Skip to main content
S&P 5007,605.41+0.26%DOW52,031.40-0.12%NASDAQ26,149.03+0.64%BTC$75,705.00-0.76%ETH$2,389.42-1.19%GOLD$4,387.70+1.27%OIL$102.69-2.97%
Smart Investors Daily
ED

NASDAQ · EDIT

Editas Medicine, Inc.

Healthcare · Biotechnology

$2.63

Up+$0.08 (+2.87%)

Updated Sep 16, 2026, 5:07 PM

SID Score

4.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
217.72M
P/E ratio
-0.91
Dividend yield
0.00%
52-week range
$1.98 – $3.94
Volume
1.68M
Avg. volume
2.47M

Price performance

EDIT price history

1M range · 20 trading sessions · Daily adjusted prices

EDIT closed at $2.63 after 20 trading sessions, down 8.68% for the selected period.

Last close
$2.63
Period change
-8.68%
Period low
$2.63
Period high
$3.30
Daily close
View OHLC price history
EDIT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$2.70$2.71$2.59$2.631.68M
Sep 14, 2026$2.72$2.815$2.66$2.741.69M
Sep 11, 2026$2.68$2.72$2.62$2.702.46M
Sep 10, 2026$2.77$2.77$2.62$2.652.55M
Sep 9, 2026$3.06$3.06$2.77$2.772.96M
Sep 8, 2026$3.20$3.215$3.01$3.032.28M
Sep 4, 2026$3.04$3.23$3.04$3.231.39M
Sep 3, 2026$3.09$3.13$3.00$3.081.38M
Sep 2, 2026$3.09$3.23$2.98$3.081.68M
Sep 1, 2026$3.00$3.155$2.98$3.071.23M
Aug 31, 2026$3.12$3.14$3.025$3.062.08M
Aug 28, 2026$3.25$3.41$3.15$3.163.27M
Aug 27, 2026$3.17$3.37$3.15$3.302.67M
Aug 26, 2026$3.40$3.515$3.16$3.182.95M
Aug 25, 2026$3.05$3.33$3.05$3.284.21M
Aug 24, 2026$3.14$3.18$2.97$3.002.06M
Aug 21, 2026$2.98$3.245$2.95$3.112.12M
Aug 20, 2026$3.17$3.2291$2.92$2.944.26M
Aug 19, 2026$3.01$3.30$2.99$3.259.64M
Aug 18, 2026$2.89$2.99$2.80$2.882.23M

Latest EDIT news

The latest Smart Investors Daily articles mentioning EDIT.

Stock researchCompany · Overview

EDIT research

Overview

Company profile and research snapshot.

Company profile

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$12.85
Implied upside
—
Analysts
—
EDIT recent ratings
DateFirmRatingTarget
Aug 18, 2026Ladenburg ThalmannBuy—
May 5, 2026Chardan CapitalBuy—
Mar 10, 2026Jones TradingBuy—
Mar 9, 2026Chardan CapitalBuy—
Sep 5, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

Editas Medicine Reports Inducement Grants to New Chief Medical Officer

CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced the grant of an inducement award to the Company’s newly appointed Chief Medical Officer, Daniel Ory, M.D. In connection with Dr. Ory’s appointment, the Editas Medicine Board of Directors approved a stock option grant to Dr. Ory as an inducement material to Dr. Ory entering into employment with Editas

Yahoo · Sep 9, 2026

Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401

Editas Medicine (NASDAQ:EDIT) is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia, Chief Executive Officer Gilmore O’Neill said during a Wells Fargo discussion. O’Ne

Yahoo · Sep 8, 2026

Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer

Dan Ory, M.D. Editas Medicine today announced the appointment of Dan Ory, M.D., as Chief Medical Officer, effective today. Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as Editas advances EDIT-401 toward clinical development CAMBRIDGE, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focu

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By